FAV 201

Drug Profile

FAV 201

Alternative Names: FAV-201; T-cell lymphoma vaccine - Favrille; Torrex

Latest Information Update: 02 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Favrille
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cutaneous T cell lymphoma

Most Recent Events

  • 30 Nov 2011 FAV 201 is available for licensing as of 30 Nov 2011. http://www.mmrvideos.com/
  • 15 Jun 2010 MMR Information Systems is now called MMRGlobal
  • 31 Jan 2009 MMR Information Systems acquires Favrille
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top